MarketPulse

Phase 2 clinical trial

9 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Gain Therapeutics to Showcase Parkinson's Drug Progress at Major Medical Conferences

Gain Therapeutics will present Phase 1b data for Parkinson's treatment GT-02287 at major conferences, with CEO appearing at ROTH Conference on March 23, 2026.
GANXPhase 2 clinical trialParkinson's disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Unveil 2025 Results as Alzheimer's Drug Advances

Acumen Pharmaceuticals will report full-year 2025 financial results on March 26, 2026, as its lead Alzheimer's candidate progresses through Phase 2 trials.
HALOABOSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Incannex Healthcare Inc.

Incannex Accelerates Sleep Apnea Drug After FDA Fast Track Win, Phase 2 Success

Incannex Healthcare receives FDA Fast Track Designation for IHL-42X sleep apnea treatment following positive Phase 2 results, plans optimized Phase 3 pathway.
IXHLPhase 2 clinical trialdrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Acumen Pharma to Present Alzheimer's Drug Data at Stifel CNS Forum

Acumen Pharmaceuticals to present Alzheimer's drug candidate sabirnetug at Stifel CNS Forum on March 18, 2026, as Phase 2 trials advance.
HALOABOSPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio's Verekitug Shows Strong Phase 2 Results in Nasal Polyp Treatment

Upstream Bio presented additional Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps, meeting primary endpoints with significant surgical intervention reduction.
UPBPhase 2 clinical trialmonoclonal antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Celldex Touts Sustained Efficacy Data for Mast Cell Antibody Barzolvolimab

Celldex's mast cell antibody barzolvolimab showed strong Phase 2 efficacy for urticaria, with 71% of patients achieving complete response. Phase 3 data expected Q4 2026.
CLDXbarzolvolimabchronic spontaneous urticaria
GlobeNewswire Inc.GlobeNewswire Inc.··Upstream Bio, Inc.

Upstream Bio to Unveil Extended VIBRANT Trial Data on Verekitug at AAAAI 2026

Upstream Bio will present expanded VIBRANT trial data on verekitug for chronic rhinosinusitis with nasal polyps at AAAAI 2026, including new efficacy analyses accounting for rescue therapy use.
UPBPhase 2 clinical trialmonoclonal antibody